about
Carvacrol codrugs: a new approach in the antimicrobial planHealth risk assessments of lithium titanate nanoparticles in rat liver cell model for its safe applications in nanopharmacology and nanomedicineEfficacy of the Quorum Sensing Inhibitor FS10 Alone and in Combination with Tigecycline in an Animal Model of Staphylococcal Infected WoundNovel NSAID-Derived Drugs for the Potential Treatment of Alzheimer's DiseaseToll-like receptor-2 agonist functionalized biopolymer for mucosal vaccination.Evidence for a dopamine intrinsic direct role in the regulation of the ovary reproductive function: in vitro study on rabbit corpora lutea.Protective effects of cyclosativene on H2O 2-induced injury in cultured rat primary cerebral cortex cells.Antiparkinson prodrugs.Prodrug approach for increasing cellular glutathione levels.Drug delivery strategies for Alzheimer's disease treatment.L-Dopa prodrugs: an overview of trends for improving Parkinson's disease treatment.Designing prodrugs for the treatment of Parkinson's disease.Potential antibacterial activity of carvacrol-loaded poly(DL-lactide-co-glycolide) (PLGA) nanoparticles against microbial biofilm.Memantine-derived drugs as potential antitumor agents for the treatment of glioblastoma.Solid lipid nanoparticles as a drug delivery system for the treatment of neurodegenerative diseases.Solid lipid nanoparticles loaded with lipoyl-memantine codrug: preparation and characterization.Synthesis of a novel cyclic prodrug of S-allyl-glutathione able to attenuate LPS-induced ROS production through the inhibition of MAPK pathways in U937 cells.Lipid nanocarriers containing a levodopa prodrug with potential antiparkinsonian activity.A glutathione derivative with chelating and in vitro neuroprotective activities: synthesis, physicochemical properties, and biological evaluation.New flurbiprofen derivatives: synthesis, membrane affinity and evaluation of in vitro effect on β-amyloid levels.Memantine-sulfur containing antioxidant conjugates as potential prodrugs to improve the treatment of Alzheimer's disease.(R)-α-lipoyl-glycyl-L-prolyl-L-glutamyl dimethyl ester codrug as a multifunctional agent with potential neuroprotective activities.New bifunctional antioxidant/σ1 agonist ligands: Preliminary chemico-physical and biological evaluation.Glycosyl and polyalcoholic prodrugs of lonidamine.HPLC-FLD and spectrofluorometer apparatus: How to best detect fluorescent probe-loaded niosomes in biological samples.L-dopa co-drugs in nanostructured lipid carriers: A comparative study.Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations.Ibuprofen and lipoic acid conjugate neuroprotective activity is mediated by Ngb/Akt intracellular signaling pathway in Alzheimer's disease rat model.Effect of 17β-estradiol on striatal dopaminergic transmission induced by permethrin in early childhood rats.Effects of early life permethrin exposure on spatial working memory and on monoamine levels in different brain areas of pre-senescent rats.Novel imidazoline compounds as partial or full agonists of D2-like dopamine receptors inspired by I2-imidazoline binding sites ligand 2-BFI.Ibuprofen and lipoic acid diamide as co-drug with neuroprotective activity: pharmacological properties and effects in beta-amyloid (1-40) infused Alzheimer's disease rat model.Ibuprofen and lipoic acid diamides as potential codrugs with neuroprotective activity.Design, synthesis, and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs.Synthesis of L-(+)-3-(3-hydroxy-4-pivaloyloxybenzyl)-2,5-diketomorpholine as potential prodrug of L-dopa.Synthesis and preliminary pharmacological evaluation of 5-hydroxy- and 5,6-dihydroxy-1,2,3,7,12,12a-hexahydrobenzo[5,6]cyclohepta[1,2,3-ij]isoquinoline derivatives as dopamine receptor ligands.Synthesis and preliminary pharmacological evaluation of trans-2-amino-5(6)-chloro-6(5)-hydroxy-1-phenyl-2,3-dihydro-1H-indenes as dopamine receptor ligands.Synthesis and activity of novel glutathione analogues containing an urethane backbone linkage.Modulation of monoaminergic transporters by choline-containing phospholipids in rat brain.NOS-mediated morphological and molecular modifications in rats infused with Aβ (1-40), as a model of Alzheimer's disease, in response to a new lipophilic molecular combination codrug-1.
P50
Q21131799-72E12A5A-55F0-4914-B09A-293DCA73656CQ28387046-D1F634BA-D167-48B7-83B1-A84D9673D310Q28552608-5DF036FA-0509-4D65-A3A2-6E3FEC0BA9D0Q28828576-D6BDEA62-8987-4016-BD3F-B041B3CAEAABQ33506880-96877001-72AB-4D0D-AF67-F42C3AA226EAQ34078432-6667302C-C15D-434B-A1EE-1D3D78C09C50Q35085926-8F15AE06-8933-44B6-89A2-CA8C8A9CF5D9Q37079678-6852BA89-7524-432B-80D8-C8A8485B57A0Q37718546-6318F128-2920-44F8-8A9C-F377B7246F8EQ37851509-9AF166C8-94EA-42A2-891E-5B6E43B5D781Q37954725-E7068BAD-AD8D-405B-944C-BABA10AFBB3BQ38001793-E0928AC1-11DF-4D15-A462-7FDF6B1946D8Q38551222-8B1A5624-35FC-4318-B163-127A3931D906Q38693650-1F8FA4AB-9471-4FFE-839F-944068D35B05Q38807256-03A58CB4-39BE-4F1C-B414-570D169358EDQ38902760-40FB2866-FA91-4D9A-B2B5-77FCFC06592AQ38942240-C5FD2C06-72BD-409E-B816-A1E3D508CC61Q39061521-34438008-E46F-4EFA-9550-7483F84B0865Q39084271-D95E9F69-1AE3-4435-B9D2-EB35D735733AQ39100139-567788C8-105B-47FC-9792-F29F50B8F5C3Q39186566-D2D9CF42-8658-494C-90B3-B90AC3D1FB8DQ39278966-724D7D36-65BC-4817-9D1E-46F3E009E5DEQ39709628-5F3CCA46-AAB8-4C6A-BD93-A2D4A0BFFDBCQ40005692-0E84382D-C263-44AF-AFB2-D69FFFFE2C3FQ40595942-87ACBCB2-94BC-49B4-A8ED-8946FBA77DA4Q41599498-8898568D-C0DE-4736-BF1E-89EAFE581D8DQ42467955-700DDECF-E01F-44EF-91A7-F3377E228AA9Q42520977-9F7320A3-BCBF-46A0-863A-0CF4DA463E19Q42704755-FEDA5023-0080-40CB-826E-96EC974C1B21Q42714132-AD7E6AF2-50FB-4814-97E3-FB095850382BQ42923558-85AFCDBE-7236-4F01-971E-94859675B763Q42964145-B9CEA909-37AF-4BF1-9C96-B5EB947D3017Q43148571-A1BBCEA6-E57C-4530-9654-B195800ABADAQ43163009-122A285C-82C3-4A11-8964-25B3A078B733Q43504961-F51D6378-ED29-4202-A51D-E4841FC3996FQ43641463-992D3294-B754-42B0-BB1F-04797C909263Q43979329-C5EC6DD1-31A2-4F0F-8783-83AD54CD7F55Q44588335-6C3E2833-85EB-40DA-ABCC-5CE703174395Q44658089-8B61D1E2-F7A6-42AC-8421-4656309F8619Q44704072-50821B87-C484-45A5-813E-A395D1A715FA
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Antonio Di Stefano
@ast
Antonio Di Stefano
@en
Antonio Di Stefano
@es
Antonio Di Stefano
@nl
type
label
Antonio Di Stefano
@ast
Antonio Di Stefano
@en
Antonio Di Stefano
@es
Antonio Di Stefano
@nl
altLabel
Antonio DI STEFANO
@en
Di Stefano A
@en
prefLabel
Antonio Di Stefano
@ast
Antonio Di Stefano
@en
Antonio Di Stefano
@es
Antonio Di Stefano
@nl
P106
P1153
35742643400
P21
P31
P4012
P496
0000-0002-3042-2234